CD46 and Miyoshi myopathy: A phase I clinical trial of CD46-ADC (FOR46, Fortis Therapeutics) has been completed in patients with relapsed or refractory MM (NCT03650491), showing single-agent activity with a partial response or better in approximately one-third of patients.